中华普通外科学文献(电子版)
中華普通外科學文獻(電子版)
중화보통외과학문헌(전자판)
CHINESE JOURNAL OF GENERAL SURGERY(ELECTRONIC VERSION)
2014年
6期
456-459
,共4页
罗吉辉%郭仪%刘晓飞%潘桂华%龙孝斌%杨熙华
囉吉輝%郭儀%劉曉飛%潘桂華%龍孝斌%楊熙華
라길휘%곽의%류효비%반계화%룡효빈%양희화
直肠癌%新辅助放化疗%全直肠系膜切除
直腸癌%新輔助放化療%全直腸繫膜切除
직장암%신보조방화료%전직장계막절제
Rectal carcinoma%Neoadjuvant chemoradiotherapy%Total mesorectal excision
目的:探讨新辅助放化疗联合全直肠系膜切除(TME)手术治疗中低位进展期直肠癌的疗效及安全性。方法回顾性分析2010年1月至2011年1月收治的56例中低位进展期直肠癌患者临床资料,28例接受新辅助放化疗联合TME手术治疗,设为观察组;28例仅接受TME手术,设为对照组。观察两组患者治疗前后TNM分期、肿瘤标志物水平及不良反应,比较两组切缘无癌细胞(R0)切除率、保肛率、局部复发率及转移率。结果观察组新辅助放化疗后TNM分期显著改善,与治疗前相比较差异有统计学意义(μ=1.960,P=0.000);癌胚抗原CEA及糖链抗原CA19-9、CA242、CA724等肿瘤标志物水平均显著降低,与治疗前相比较差异有统计学意义(t值分别为9.276、8.716、9.420、6.512,均P<0.01)。观察组R0切除率(89.28%vs 60.71%,χ2=6.095,P=0.014)及保肛率(75.00%vs 32.14%,χ2=10.338,P=0.001)均显著高于对照组。随访1年,观察组术后局部复发率(7.14%vs 28.57%,χ2=4.383,P=0.036)及远处转移率(21.43%vs 46.43%,χ2=3.903,P=0.048)显著低于对照组,差异有统计学意义。结论新辅助放化疗联合TME手术治疗中低位局部进展期直肠癌疗效确切,值得临床推广使用。
目的:探討新輔助放化療聯閤全直腸繫膜切除(TME)手術治療中低位進展期直腸癌的療效及安全性。方法迴顧性分析2010年1月至2011年1月收治的56例中低位進展期直腸癌患者臨床資料,28例接受新輔助放化療聯閤TME手術治療,設為觀察組;28例僅接受TME手術,設為對照組。觀察兩組患者治療前後TNM分期、腫瘤標誌物水平及不良反應,比較兩組切緣無癌細胞(R0)切除率、保肛率、跼部複髮率及轉移率。結果觀察組新輔助放化療後TNM分期顯著改善,與治療前相比較差異有統計學意義(μ=1.960,P=0.000);癌胚抗原CEA及糖鏈抗原CA19-9、CA242、CA724等腫瘤標誌物水平均顯著降低,與治療前相比較差異有統計學意義(t值分彆為9.276、8.716、9.420、6.512,均P<0.01)。觀察組R0切除率(89.28%vs 60.71%,χ2=6.095,P=0.014)及保肛率(75.00%vs 32.14%,χ2=10.338,P=0.001)均顯著高于對照組。隨訪1年,觀察組術後跼部複髮率(7.14%vs 28.57%,χ2=4.383,P=0.036)及遠處轉移率(21.43%vs 46.43%,χ2=3.903,P=0.048)顯著低于對照組,差異有統計學意義。結論新輔助放化療聯閤TME手術治療中低位跼部進展期直腸癌療效確切,值得臨床推廣使用。
목적:탐토신보조방화료연합전직장계막절제(TME)수술치료중저위진전기직장암적료효급안전성。방법회고성분석2010년1월지2011년1월수치적56례중저위진전기직장암환자림상자료,28례접수신보조방화료연합TME수술치료,설위관찰조;28례부접수TME수술,설위대조조。관찰량조환자치료전후TNM분기、종류표지물수평급불량반응,비교량조절연무암세포(R0)절제솔、보항솔、국부복발솔급전이솔。결과관찰조신보조방화료후TNM분기현저개선,여치료전상비교차이유통계학의의(μ=1.960,P=0.000);암배항원CEA급당련항원CA19-9、CA242、CA724등종류표지물수평균현저강저,여치료전상비교차이유통계학의의(t치분별위9.276、8.716、9.420、6.512,균P<0.01)。관찰조R0절제솔(89.28%vs 60.71%,χ2=6.095,P=0.014)급보항솔(75.00%vs 32.14%,χ2=10.338,P=0.001)균현저고우대조조。수방1년,관찰조술후국부복발솔(7.14%vs 28.57%,χ2=4.383,P=0.036)급원처전이솔(21.43%vs 46.43%,χ2=3.903,P=0.048)현저저우대조조,차이유통계학의의。결론신보조방화료연합TME수술치료중저위국부진전기직장암료효학절,치득림상추엄사용。
Objective To evaluate the effect and security of neoadjuvant chemoradiotherapy in combination with total mesorectal excision (TME) in treatment of advanced middle and lower rectal carcinoma. Methods Fifty-six patients of advanced middle and lower rectal carcinoma were retrospectively recruited and divided into observation group and control group from January 2010 to January 2011, with 28 cases in each group. Neoadjuvant chemoradiotherapy combined with TME were given to observation group and TME alone was performed in control group. TNM stage, tumor marker levels and adverse reactions were recorded before and after neoadjuvant chemoradiation. The R0 radical resection rate, sphincter preservation rate, local recurrence rate and metastasis rate were compared between the two groups. Results After neoadjuvant chemoradiation, the TNM stage in observation group improved significantly, the difference statistically significant compared with that before treatment (μ=1.960,P=0.000). In the meantime, the levels of CEA, CA19-9, CA242 and CA724 in observation group significantly decreased, and the difference was statistically significant compared with that before treatment (t=9.276, 8.716, 9.420, 6.512, all P<0.01). The R0 radical resection rate and sphincter preservation rate of observation group were significantly higher than control group (89.28%vs 60.71%,75.00%vs 32.14%,χ2=6.095, 10.338, P=0.014, 0.001). After a 1-year follow-up, local recurrence rate and metastasis rate of observation group were significantly lower than those of control group, with statistically significant differences (7.14%vs 28.57%, 21.43%vs 46.43%,χ2=4.383, 3.903, P=0.036, 0.048). Conclusion Neoadjuvant chemoradiotherapy combined with TME can obtain improved curative effect in treatment of advanced middle and lower rectal carcinoma, and it is worthy of clinical application.